NCT05653453

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 512 (estimated)
• Sponsor: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.

Conditions

• Locally Advanced Pancreatic Cancer

Interventions

Type	Name	Description
DEVICE	Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel	Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months. Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
DRUG	Gemcitabine hydrochloride and albumin binding paclitaxel	Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.

Timeline

• Start date: 2022-12-20
• Primary completion: 2026-12-25
• Completion: 2027-09-28
• First posted: 2022-12-16
• Last updated: 2025-03-24

Locations

5 sites across 1 country: China